Savient Pharmaceuticals Files For Ch. 11, Plans $55M Sale
New Jersey-based Savient — which posted roughly $73.8 million in assets against nearly $260.4 million in liabilities as of June 30 — and its sole U.S. subsidiary sought court protection after the drug developer's flagship product Krystexxa failed to carry the company to profitability.
Savient saw its cash...
To view the full article, register now.